SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!
李新宇
Lv4
530 积分
2023-04-30 加入
最近求助
最近应助
互助留言
Landscape of young breast cancer under 35 years in China over the past decades: a multicentre retrospective cohort study (YBCC-Catts study)
9天前
已完结
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
1个月前
已完结
Deciphering breast cancer: from biology to the clinic
6个月前
已完结
[Expert consensus on endocrine therapy of breast cancer (2023 edition)]
6个月前
已完结
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
10个月前
已完结
Cancer statistics, 2023
10个月前
已完结
352TiP EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC)
11个月前
已完结
175P Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study
11个月前
已完结
Abstract P5-13-03: Alpelisib + endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study
11个月前
已关闭
LBA18 POSEIDON randomized phase II trial: Tamoxifen (TAM) + taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC)
11个月前
已完结
没有进行任何应助
感谢
9天前
感谢
6个月前
感谢
6个月前
感谢
10个月前
输入内容有误【积分已退回】
11个月前
感谢
11个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论